Clinical studies have shown that locally advanced or metastatic NSCLC patients harboring ALK gene rearrangement are highly sensitive to Crizotinib, which is a small molecular inhibitor of ALK tyrosine kinase [8, 9]. Here, ALK is linked to non-small cell lung carcinoma.